The clinical significance of circulating B cells secreting anti-glycoprotein IIb/IIIa antibody and platelet glycoprotein IIb/IIIa in patients with primary immune thrombocytopenia

Hematology

Volumn 17, Issue 5, 2012, Pages 283-290

  Chen, Jian fang ^a   Yang, Lin hua ^a   Chang, Li xian ^a   Feng, Jian jun ^a   Liu, Jun qing ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Anti glycoprotein IIb IIIa antibody; Enzyme linked immunospot assay; Glycoprotein IIb IIIa; Monoclonal antibody immobilization of platelet antigens assay; Primary immune thrombocytopenia

Indexed keywords

FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMOBILIZATION; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MONOCLONAL ANTIBODY IMMOBILIZATION OF PLATELET ANTIGENS ASSAY; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; PROTEIN SECRETION; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA;

ADULT; AUTOANTIBODIES; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE COUNT; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84866057080     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000014     Document Type: Article

References (42)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995-1008.
2. Cooper N, Bussel J. The pathogenesis of immune thrombocyto- penic purpura. Br J Haematol. 2006;133(4):364-74.
3. Neunert C, Lim W, Crowther M, Cohen A, Solberg L. Jr, Crowther MA, et al. The American Society 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-207.
4. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79(4):504-22.
5. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80(1):33-40.
6. McMillan R. Autoantobodies and autoantigens in chronic immune thrombocytopenia purpura. Semin Hematol. 2000; 37(3):239-48.
7. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146(6):585-96.
8. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3): 887-95.
9. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoanti-bodies from adult patients with chronic ITP. Blood. 2004; 103(4):1364-9.
10. Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, et al. Improved regulatory T cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639-45.
11. Zhang F, Chu X, Wang L, Zhu Y, Li L, Ma D, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006;76(5):427-31.
12. Olsson B, Andersson PO, Jernås M, Jacobbson S, Carlsson B, Carlsson LM, et al. T-cellmediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-4.
13. Hou M, Stockelberg D, Kutti J, Waldenvik H. Antibodies against GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 1995;55(5):307-14.
14. Mehta YS, Pathare AV, Badakere SS, Ghosh K, Mohanty D. Influence of auto-antibody specificities on the clinical course in patients with chronicand acute ITP. Platelets. 2000;11(2):94-8.
15. Fabris F, Scandellari R, Ruzzon E, Randi ML, Luzzato G, Girolami A. Plateletassociated autoantibodies as detected by a solidphase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood. 2004;103(12):4562-4.
16. van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocyto-penia. Blood. 1982;59(1):23-6.
17. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood. 1994; 83(4):1024-32.
18. Woods VL, Jr, Oh EH, Mason D, McMillan R. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood. 1984;63(2):368-75.
19. Fujisawa K, Tani P, McMillan R. Plateletassociated antibody to glycoprotein IIb/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cation-dependent anti- gens. Blood. 1993;81(5):1284-9.
20. Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2003;122(5):818-24.
21. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 1983;65(1-2):109-21.
22. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of glycoprotein IIb-IIIa-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002;168(7):3657-82.
23. Kuwana M, Okazaki Y, Kaburaki J, Ikeda Y. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med. 2003;114(4):322-5.
24. Satoh T, Pandey JP, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y, et al. Single nucleotide polymorphisms of the inflammatory cytokine genes in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;124(6):796-801.
25. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Int Med. 2000;160(11):1630-8.
26. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investi- gation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86.
27. Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70(6):353-7.
28. McMillan R. The pathogenesis of chronic immune thrombocy-topenic purpura. Semin Hematol. 2007;44(4 Suppl 5):S3-S11.
29. + T cells in patients with idio- pathic thrombocytopenic purpura. Thromb Res. 2007;120(2): 187-93.
30. + regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008; 112(4):1325-8.
31. Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112(4): 1147-50.
32. Mueller-Eckhardt C, Kayser W, Mersch-Baumert K, Mueller-Eckhardt G, Breidenbach M, Kugel HG, et al. The significance of platelet-associated IgG: a study on 298 patients with various disorders. Br J Haematol. 1980;46(1):123-31.
33. Kelton JG, Powers PJ, Carter CJ. A prospective study of the use-fulness of the measurement of platelet-associated IgG for the diagnosis idiopathic thrombocytopenic purpura. Blood. 1982; 60(4):1050-3.
34. Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenia. Blood. 1996; 88(1):194-201.
35. Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol. 1999; 104(3):442-7.
36. Raife TJ, Olson JD, Lentz SR. Platelet antibody testing in idiopathic thrombocytopenic purpura. Blood. 1997;89(3): 1112-4.
37. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009; 113(26):6511-21.
38. Wang JY, Chou CH, Lee LN, Hsu HL, Jan IS, Hsueh PR, et al. Diagnosis of tuberculosis by an enzyme-linked immunospot assay for interferon-gamma. Emerg Infect Dis. 2007;13(4): 553-8.
39. Sedgwick JD. ELISPOT assay: a personal retrospective. Methods Mol Biol. 2005;302:3-14.
40. Kuwana M, Kurata Y, Fujimura K, Fujisawa K, Wada H, Nagasawa T, et al. Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by muti-center prospective study. J Thromb Haemost. 2006;4(9): 1936-43.
41. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood. 1988;71(4): 831-43.
42. Kuwana M, Kaburaki J, Kitasato H, Kato M, Kawai S, Kawakami Y, et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood. 2001;98(1):130-9.